Investors Should Prioritize This Aspect of Moderna

By Tamara Parker • Friday, February 09 15:38 • Permanent Link

One of the losers of today's trading session was Moderna. Shares of the Biotechnology company plunged -6.4%, and some investors may be wondering if its price of $87.64 would make a good entry point. Here's what you should know if you are considering this investment:

Moderna has moved -44.7% over the last year, and the S&P 500 logged a change of 22.2%
MRNA has an average analyst rating of buy and is -32.22% away from its mean target price of $129.29 per share
Its trailing earnings per share (EPS) is $-9.23
Moderna has a trailing 12 month Price to Earnings (P/E) ratio of -9.5 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $-6.87 and its forward P/E ratio is -12.8
The company has a Price to Book (P/B) ratio of 2.48 in contrast to the S&P 500's average ratio of 2.95
Moderna is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
The company has a free cash flow of $-1105874944, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a strategic partnership with Caris Life Sciences to advance mRNA-Based oncology therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.